NDA 202736 approval letter – Sklice (ivermectin) Lotion, 0.5%, for head lice (2012)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research · February 7, 2012

U.S. Food et al., 2012-02-07: FDA approval letter for the topical head-lice lotion, addressed to Sanofi-Topaz, Inc.

This new drug application provides for the use of Sklice (ivermectin) Lotion, 0.5% for the topical treatment of head lice infestations in patients 6 months of age and older.

1

U.S. Food et al., 2012-02-07: FDA approval letter for the topical head-lice lotion, addressed to Sanofi-Topaz, Inc. C6 Sklice. Record fields: NDA 202736, applicant 'Sanofi-Topaz, Inc.', Horsham PA; application dated and received April 7, 2011, submitted under section 505(b) of the FD&C Act; approved 2012-02-07. Current holder per the Drugs@FDA record is Arbor Pharmaceuticals LLC and the product's marketing status is now 'Over-the-counter' (openFDA Drugs@FDA query, 2026-11-19), which post-dates this letter. Study type: regulatory record.